Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.48 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.45 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2473487 | 0.86 | ALDH1A1 (0.50) | ALDH1A1TACR1CHRM5CHRM3PLA2G1B | |
| SCHEMBL2471940 | 0.85 | TACR3 (0.44) | ALDH1A1TACR1OPRL1LMNARAB9A | |
| SCHEMBL13593924 | 0.84 | ALDH1A1 (0.67) | ALDH1A1TACR1OPRL1RAB9APKM | |
| SCHEMBL2469740 | 0.82 | TACR1 (0.48) | TACR1OPRL1CHRM5CHRM3CHRM4 | |
| SCHEMBL2513448 | 0.81 | ALDH1A1 (0.58) | ALDH1A1TACR1OPRL1LMNAPKM | |
| SCHEMBL5345935 | 0.79 | TRPA1 (0.48) | ALDH1A1TACR1OPRL1TP53MDM2 | |
| SCHEMBL5349800 | 0.79 | SMN1; SMN2 (0.55) | TACR1CHRM5CHRM3LMNATP53 | |
| SCHEMBL2701062 | 0.79 | KMT2A (0.53) | ALDH1A1OPRL1RAB9APKM | |
| SCHEMBL13183011 | 0.79 | ALDH1A1 (0.74) | ALDH1A1TACR1OPRL1CHRM5CHRM3 | |
| SCHEMBL2513103 | 0.78 | CHRM5 (0.49) | TACR1CHRM5CHRM3CHRM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371366-A1 | Heterocyclo inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-17 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582654-B2 | Heterocyclo inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312307-A1 | HETEROCYCLO INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNH2, KCNQ5 | ALDH1A1 3941/4885TACR1 3354/4885OPRL1 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.